Janssen Vaccines & Prevention B.v.

Crucell Holland B.v.

Bavarian Nordic A/s

Jerôme H H V Custers

Jort Vellinga

Selina Khan

Taco Gilles Uil

Soumitra Roy

Katarina Radosevic

Evelien Margaretha Bunnik

Gerrit Christiaan Scheper

Myra N Widjojoatmodjo

Markus Kalla

Koen Oosterhuis

Kerstin Wunderlich

Barbara Petronella Sanders

Marija Vujadinovic

Katrin Weidner

Esmerelda Van Der Helm

Evelien M Bunnik

Gerrit Ch Scheper

Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.

Adenovirus and uses thereof

The invention provides recombinant adenovirus (rAd) and rAd vectors comprising a bidirectional mouse CMV (mCMV) promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such rAd and rAd vectors.

Recombinant adenovirus expressing two transgenes with a bidirectional promoter

The present invention relates to novel vaccines against malaria infections, based on recombinant adenovirus vectors. Described are capsid modified replication deficient adenovirus particle encoding and displaying circumsporozoite (CS) protein NANP-repeats (CS) from a malaria-causing parasite, preferably, via a minor capsid protein IX and encoding a heterologous protein as a transgene. In a particular embodiment, said replication incompetent vectors of rare serotypes such as human adenovirus 35 (HAdV35) and human adenovirus 26 (HAdV26) comprise nucleic acid encoding the CS protein, as a transgene, from a malaria-causing parasite and encoding and displaying the NANP-repeat from a malaria-causing parasite (1) directly fused to the protein IX, (2) fused to protein IX via a flexible linker or (3) an alpha-helical viral origin spacer SP1 to ensure both humoral and cellular responses against the selected antigens.

Adenovirus based malaria vaccine encoding and displaying a malaria antigen

Vectors, vaccines, vaccine compositions and vaccine combinations for use as therapeutics against HPV18 and/or HPV16 are described.

Therapeutic HPV vaccine combinations

Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV16.

Therapeutic HPV16 vaccines

Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype 26 that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.

Vaccine against RSV

Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.

Described is a composition comprising a plurality of recombinant adenovirus particles, being a recombinant human adenovirus of serotype 5, 26, 34, 35, 48, 49 or 50, or a recombinant simian adenovirus, characterized in that the genomes of essentially all adenovirus particles in the composition comprise as the 5' terminal nucleotides the nucleotide sequence: CTATCTAT (nucleotides 1-8 of SEQ ID NO:7). Also described are methods to produce such compositions.

Growing community of inventors

Alphen aan den Rijn, Netherlands

Jerôme H H V Custers